| Literature DB >> 36207323 |
Ankur Chakravarthy1, Ian Reddin2, Stephen Henderson3, Cindy Dong4, Nerissa Kirkwood4, Maxmilan Jeyakumar4, Daniela Rothschild Rodriguez4, Natalia Gonzalez Martinez4, Jacqueline McDermott5, Xiaoping Su6, Nagayasau Egawa7, Christina S Fjeldbo8, Vilde Eide Skingen8, Heidi Lyng8,9, Mari Kyllesø Halle10, Camilla Krakstad10, Afschin Soleiman11, Susanne Sprung12, Matt Lechner5, Peter J I Ellis4, Mark Wass4, Martin Michaelis4, Heidi Fiegl13, Helga Salvesen10, Gareth J Thomas2, John Doorbar7, Kerry Chester14, Andrew Feber15,16, Tim R Fenton17,18,19.
Abstract
Human papillomavirus (HPV)-associated cervical cancer is a leading cause of cancer deaths in women. Here we present an integrated multi-omic analysis of 643 cervical squamous cell carcinomas (CSCC, the most common histological variant of cervical cancer), representing patient populations from the USA, Europe and Sub-Saharan Africa and identify two CSCC subtypes (C1 and C2) with differing prognosis. C1 and C2 tumours can be driven by either of the two most common HPV types in cervical cancer (16 and 18) and while HPV16 and HPV18 are overrepresented among C1 and C2 tumours respectively, the prognostic difference between groups is not due to HPV type. C2 tumours, which comprise approximately 20% of CSCCs across these cohorts, display distinct genomic alterations, including loss or mutation of the STK11 tumour suppressor gene, increased expression of several immune checkpoint genes and differences in the tumour immune microenvironment that may explain the shorter survival associated with this group. In conclusion, we identify two therapy-relevant CSCC subtypes that share the same defining characteristics across three geographically diverse cohorts.Entities:
Mesh:
Year: 2022 PMID: 36207323 PMCID: PMC9547055 DOI: 10.1038/s41467-022-33544-x
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 17.694